Loading...
•
Dec 31, 2022
P3 Health Q4 2022 Earnings Report
Announced fourth quarter and full-year 2022 results, affirming 2023 guidance and introducing year-end medical margin guidance.
Key Takeaways
P3 Health Partners announced their Q4 2022 financial results, highlighting revenue growth and a network contribution improvement of 65% versus 2021. The company secured financing of approximately $90.0 million and anticipates reaching Adjusted EBITDA positive in early 2024.
Achieved revenue growth in 2022.
Improved network contribution by 65% versus 2021.
Secured financing of approximately $90.0 million.
Anticipates reaching Adjusted EBITDA positive in early 2024.
Forward Guidance
P3 Health Partners affirmed its 2023 guidance and expects to reach Adjusted EBITDA positive in early 2024, driven by a shift to a higher percentage of persistent lives, reduced operating expenses, and measured growth.
Positive Outlook
- Shift to a higher percentage of persistent lives.
- Focused reduction in operating expenses.
- Measured and disciplined growth in 2023.
- Expectation to achieve Adjusted EBITDA profitability in 2024.
- Secured financing of approximately $90.0 million provides a solid path to profitability.
Challenges Ahead
- Actual results may differ materially depending on a number of factors.
- Changes in market or industry conditions.
- Regulatory environment and competitive conditions.
- Impact of COVID-19, including the impact of new variants of the virus, or another pandemic, epidemic or outbreak of infectious disease on our business and results of operation.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...